West Pharmaceutical Services, Inc. (LON:0ADY)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 18.30B +42.1% |
| Revenue (ttm) | 2.51B +12.4% |
| Net Income | 425.77M +15.8% |
| EPS | 5.89 +16.8% |
| Shares Out | n/a |
| PE Ratio | 42.99 |
| Forward PE | 37.93 |
| Dividend | 0.66 (0.25%) |
| Ex-Dividend Date | Apr 29, 2026 |
| Volume | 43 |
| Open | 353.06 |
| Previous Close | 346.82 |
| Day's Range | 353.06 - 353.06 |
| 52-Week Range | 236.01 - 363.84 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 23, 2026 |
About LON:0ADY
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhanc... [Read more]
Financial Performance
In 2025, LON:0ADY's revenue was $3.07 billion, an increase of 6.25% compared to the previous year's $2.89 billion. Earnings were $493.70 million, an increase of 0.20%.
Financial numbers in USD Financial StatementsNews
West Pharmaceutical price target raised to $412 from $400 at Citi
Citi raised the firm’s price target on West Pharmaceutical (WST) to $412 from $400 and keeps a Buy rating on the shares.
West Pharmaceutical price target raised to $425 from $410 at Evercore ISI
Evercore ISI raised the firm’s price target on West Pharmaceutical (WST) to $425 from $410 and keeps an Outperform rating on the shares.
West Pharmaceutical price target raised to $410 from $400 at BofA
BofA raised the firm’s price target on West Pharmaceutical (WST) to $410 from $400 and keeps a Buy rating on the shares after what the firm calls “another beat and…
GLP-1 concerns around West Pharmaceutical feel overdone, says Evercore ISI
Evercore ISI reiterated an Outperform rating and $410 price target on West Pharmaceutical (WST) after the company reported quarterly results. The firm said the main questions it has received Thursday…
West Pharmaceutical Services Earnings Call Transcript: Q2 2026
Q2 2026 saw double-digit revenue and EPS growth, driven by strong HVP components and biologics demand, with robust performance across all geographies. Full-year guidance was raised, reflecting high teens growth in HVP components and continued margin expansion.
West Pharmaceutical Services Earnings release: Q2 2026
West Pharmaceutical Services released its Q2 2026 earnings on July 23, 2026, summarizing the period's financial results.
West Pharmaceutical Services Slides: Q2 2026
West Pharmaceutical Services has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 23, 2026.
West Pharmaceutical Services Quarterly report: Q2 2026
West Pharmaceutical Services has published its Q2 2026 quarterly earnings report on July 23, 2026.
West Pharmaceutical raises annual profit forecast on strong demand for injectable drug components
West Pharmaceutical Services raised its annual profit and revenue forecasts on Thursday as strong demand for components used in injectable drugs, including diabetes and obesity treatments, helped it...
West Reports Second-Quarter 2026 Results
Raising Full-Year Net Sales and EPS guidance EXTON, Pa., July 23, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutio...
West Declares Quarterly Dividend
EXTON, Pa., July 21, 2026 /PRNewswire/ -- On July 21, 2026, the Board of Directors of West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug admini...
West Pharmaceutical price target raised to $410 from $365 at TD Cowen
TD Cowen raised the firm’s price target on West Pharmaceutical (WST) to $410 from $365 and keeps a Buy rating on the shares. The firm cites an improved earnings outlook…
West Pharmaceutical initiated with an Outperform at BNP Paribas
BNP Paribas initiated coverage of West Pharmaceutical (WST) with an Outperform rating and $447 price target
West Pharmaceutical price target raised to $365 from $325 at Morgan Stanley
Morgan Stanley raised the firm’s price target on West Pharmaceutical (WST) to $365 from $325 and keeps an Equal Weight rating on the shares. The firm is updating its model…
West to Host Second-Quarter 2026 Conference Call
EXTON, Pa., July 7, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will releas...
West Pharmaceutical price target raised to $410 from $390 at Evercore ISI
Evercore ISI analyst Daniel Markowitz raised the firm’s price target on West Pharmaceutical (WST) to $410 from $390 and keeps an Outperform rating on the shares. The firm’s Q2 preview…
West Pharmaceutical price target raised to $390 from $350 at KeyBanc
KeyBanc raised the firm’s price target on West Pharmaceutical (WST) to $390 from $350 and keeps an Overweight rating on the shares. The firm cites increased confidence in West Pharmaceutical…
West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
EXTON, Pa., July 1, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced the company complet...
Barclays upgrades West Pharmaceutical on ‘material’ upside to estimates
Barclays analyst Luke Sergott upgraded West Pharmaceutical (WST) to Overweight from Equal Weight with a price target of $400, up from $310. The firm says it overestimated the risk from…
West Pharmaceutical upgraded to Overweight from Equal Weight at Barclays
Barclays upgraded West Pharmaceutical (WST) to Overweight from Equal Weight with a $400 price target
West Pharmaceutical Services Transcript: 46th Annual William Blair Growth Stock Conference
Strong growth in high-value injectable medicine components, driven by biologics, GLP-1s, and regulatory changes, is fueling double-digit margin and EPS expansion. Leadership transition to a new CEO aligns with strategic growth, supported by robust cash flow and global market presence.
West Pharmaceutical Services Slides: 46th Annual William Blair Growth Stock Conference
West Pharmaceutical Services has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
West Pharma names former Thermo Fisher executive Lagarde as CEO
West Pharmaceutical said on Monday it appointed former Thermo Fisher Scientific executive Michel Lagarde as its top boss, effective August 31, succeeding longtime chief Eric Green.
West Pharmaceutical says Michel Lagarde to succeed Eric Green as CEO
West Pharmaceutical (WST) Services announced that its Board of Directors has appointed Michel Lagarde to be President and CEO and a member of the company’s Board of Directors starting August…
West Pharmaceutical assumed with Outperform at Wolfe Research
As previously reported, Wolfe Research analyst Mike Polark upgraded West Pharmaceutical (WST) to Outperform from Peer Perform with a $375 price target Q1 was “juicy good,” driven by continued GLP1…